BioWorld looks at translational medicine, including: Exosomes deliver sepsis treatment; Dopamine has epigenetic role in addiction; Rejuvenating inflammation’s end; Gut repair with an iron will; Multiple drivers explained.
“Vaccines, obviously, are the ultimate solution for pandemics,” Rino Rappuoli told BioWorld. They have, he added, “already eliminated a lot of pandemic threats – smallpox, influenza, poliomyelitis.” And the road to normalcy from the current pandemic, or any pandemic, is likely to be open only once there is a vaccine.
Specific therapies against a new disease take time to develop. But there are methods that can speed up that development – and in the meantime, there are ways to make do with what’s already in the cupboard.
Tyto Care Ltd. nabbed $50 million in an oversubscribed round of funding the company will use to expand commercialization of its integrated telehealth platform and remote device with examination tools, which has seen a surge in demand with COVID-19. The new cash nearly doubles the New York-based company's total funding, bringing it to $105 million. Insight Partners, Olive Tree Ventures, and Qualcomm Ventures LLC led the latest round.
COVID-19 has disrupted science in the way it has disrupted everything else. In the short term, universities have largely closed shop as a way to maximize social distancing, and lots of science – or at least, lots of bench work – is not getting done.
Keeping you up to date on recent developments in oncology, including: Technetium crunch resurfaces as COVID-19 roils the globe; Microbiome changes precede tumor development in CRC; Il-27 proposed as target in prostate cancer.
“In any crisis, leaders have two equally important responsibilities: solve the immediate problem and keep it from happening again... The first point is more pressing, but the second has crucial long-term consequences.” So wrote Bill Gates in a February editorial in The New England Journal of Medicine about COVID-19, which “has started behaving a lot like the once-in-a-century pathogen we’ve been worried about.”
COVID-19 has disrupted science in the way it has disrupted everything else. In the short term, universities have largely closed shop as a way to maximize social distancing, and lots of science – or at least, lots of bench work – is not getting done.
Keeping you up to date on recent developments in neurology, including: Engineers 3D print brain implants; Minimal phenotyping gives minimal insights into MDD genetics; Optogenetic plaque model traces neurodegeneration in AD; Once repulsive, always repulsive.
BioWorld looks at translational medicine, including: Microbiome changes precede tumor development in CRC; Converting catch and release to PARP traps; Smart bacterium senses environment; The dose makes the poison – timing, too; Minimal phenotyping gives minimal insights into MDD genetics; Hypoxia linked to common form of muscular dystrophy; Stopping tau in its tracks; Optogenetic plaque model traces neurodegeneration in AD; Once repulsive, always repulsive.